Ari Fujishiro
Corporate Officer & Head of IR & SR Dept., Global Corporate Affairs
[interpreted]
Thank you for waiting. We are going to start Daiichi Sankyo’s FY 2025 Financial Results Announcement and FY 2026-FY 2030 5-year business plan presentation and discussion. I’m delighted to serve as MC today.
I’m Ari Fujishiro from the Investor Relations and Shareholder Relations Department. First, about the language. In this briefing session, we are going to use Japanese and English. Simultaneous translation is available. [Operator Instructions] On Zoom screen and during live streaming, we will show a presentation material in Japanese. We have posted a presentation in both Japanese and English on our corporate website under IR library, financial results presentation material or IR Presentation Materials section. Please download the files if necessary.
Today, 5 members are in attendance. Representative Director, President and CEO, Hiroyuki Okuzawa; Senior Executive Officer, CFO; Tomohiro Kodama; Director, Head of Oncology Business Unit, Ken Keller, Head of Global R&D, John Tsai, Senior Executive Officer, Head of R&D Division, Yuki Abe.
Today, after
